BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic – Calgary Herald

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today …